Biosimilar Antibodies

Narnatumab (IMC-RON8) is a human monoclonal antibody designed to neutralize RON receptor activity by inhibiting its interaction with the macrophage-stimulating protein (MSP). This antibody demonstrates a high affinity for the RON receptor with a dissociation constant (Kd) of 32 pM. Narnatumab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the RON receptor in tumor progression and metastasis.

Firivumab (CT-P22; CT120) is a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA). This antibody demonstrates a broad neutralizing capacity against multiple subtypes including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. In vivo studies have confirmed Firivumab's protective efficacy against the H1N1 virus in murine models, highlighting its potential for therapeutic applications in influenza A virus infections.

Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.

Roconkibart is a human IgG4 κ monoclonal antibody targeting IL-17A. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and neutralization of IL-17A, a key cytokine involved in inflammatory processes and autoimmune disorders.

IMA-026 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and possesses a predicted molecular weight of 146.88 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Galiximab (IDEC 114) is a primatized monoclonal antibody of the immunoglobulin G1 (IgG1) lambda class, specifically targeting the CD80 antigen to inhibit the CD80-CD28 interaction. This antibody features variable regions derived from cynomolgus monkeys and human constant regions. Galiximab is commonly utilized in the study of B-cell lymphoma, providing a valuable tool for investigating the role of CD80 in immune modulation and cancer biology.

Inezetamab is a bispecific IgG1 monoclonal antibody that targets both CD40 and mesothelin (MSLN). This dual specificity enables it to engage multiple pathways involved in immune modulation and tumor cell targeting, making it a valuable tool for research in cancer immunotherapy and related fields.

Delpacibart is a humanized IgG1κ monoclonal antibody specifically designed to target the transferrin receptor (TFRC). TFRC is a critical membrane protein that plays a pivotal role in regulating intracellular iron transport. This antibody is instrumental in studies focusing on iron metabolism and related cellular processes.

The Anti-TPSAB1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TPSAB1 protein, which is critical in various biological processes. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG4 kappa, Isotype Control is recommended.

Brivekimig is a chimeric antibody composed of five variable heavy (VH) domains, specifically designed to target TNFSF4, TNFSF2, and albumin (ALB). This unique configuration enhances its specificity and binding affinity, making it an ideal tool for research into the signaling pathways and biological effects mediated by these targets. Brivekimig is suitable for use in various experimental contexts to elucidate the roles of TNFSF4 and TNFSF2 in immune regulation and inflammatory processes.

Suvonstobart is a monoclonal antibody that specifically targets human CD24, a signal transducer integral to various immune cell signaling pathways. By binding to CD24, Suvonstobart activates these pathways, demonstrating both immunostimulatory and antitumor properties. This antibody is utilized primarily in research focused on cancer immunotherapy and the modulation of immune responses.

Lifastuzumab is a humanized monoclonal antibody of the IgG1 subtype, targeting the sodium-dependent phosphate transport protein 2b (NaPi2b). This antibody can be conjugated to monomethyl auristatin E (MMAE) via an ADC linker, creating the antibody-drug conjugate lifastuzumab vedotin (DNIB0600A). The resulting conjugate exhibits potent anticancer activity, making it a valuable tool for targeted cancer therapy research.

Budigalimab (ABBV 181; PR 1648817) is a humanized recombinant IgG1 monoclonal antibody specifically designed to target the programmed cell death 1 (PD-1) receptor. This antibody features a modified Fc region with a mutation that diminishes Fc receptor interactions and effector function inhibition. By effectively blocking the interaction between PD-1 and its ligand PD-L1, Budigalimab exhibits potent anti-tumor activity. It is primarily utilized in research focused on various solid tumors, providing a valuable tool for oncology studies.

Telazorlimab (GBR-830) is a humanized monoclonal antibody designed to target the OX40 costimulatory receptor, which is expressed on activated T cells. This antibody is utilized primarily in the study of autoimmune diseases, offering a valuable tool for researchers exploring the modulation of T cell responses in various immunological conditions.

Vunakizumab is a recombinant human IgGκ monoclonal antibody specifically designed to target and neutralize interleukin-17A (IL-17A). By binding to IL-17A, Vunakizumab effectively prevents its interaction with the IL-17 receptor, thereby inhibiting the pro-inflammatory pathways associated with this cytokine. This antibody is particularly useful in research focused on autoimmune disorders, including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis, where IL-17A plays a key role in disease pathogenesis.

Olinvacimab (TTAC-0001) is a fully human monoclonal antibody targeting VEGFR2, exhibiting potent antiangiogenic properties. This antibody binds specifically to the kinase insert domain receptor (KDR), a known alias for VEGFR2, with a high affinity characterized by a dissociation constant (Kd) of 0.23 nM. By inhibiting the vascular endothelial growth factor (VEGF) pathway, Olinvacimab effectively disrupts tumor angiogenesis. It is primarily utilized in research focused on investigating therapeutic approaches for recurrent glioblastoma and breast cancer.

Nebokitug is a human monoclonal antibody of the IgG1κ isotype designed to specifically target CCL24. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

VLST-002 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

DCBY02 is a pioneering humanized IgG1 monoclonal antibody specifically developed to target CD93. This antibody is engineered to normalize tumor vasculature, thereby enhancing the infiltration of immune cells into the tumor microenvironment. Its mechanism promotes the efficacy of concurrent cancer immunotherapies, making it a valuable tool for advancing oncological research and therapeutic development.

The Anti-DDR1/CD167a Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DDR1/CD167a, a receptor tyrosine kinase implicated in the regulation of cell growth and differentiation. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in research applications focusing on cellular signaling, cancer biology, and developmental processes.

Rinucumab (REGN 2176) is a monoclonal antibody designed to inhibit platelet-derived growth factor (PDGF), making it a valuable tool for research into neovascular age-related macular degeneration. This antibody specifically targets PDGF pathways, which are implicated in the pathological angiogenesis associated with this condition. Rinucumab (REGN 2176) is utilized primarily in studies aimed at understanding and potentially mitigating the progression of neovascular age-related macular degeneration.

Xeligekimab (GR 1501) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin 17A (IL-17A), a key cytokine involved in the induction and maintenance of pro-inflammatory responses. By binding to IL-17A, Xeligekimab effectively inhibits the cytokine's interaction with its receptor, thereby disrupting the pro-inflammatory cascade. This antibody is utilized in research focused on inflammatory diseases to understand the role of IL-17A in disease pathology and to evaluate potential therapeutic interventions.

Marstacimab (PF-06741086) is a monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI). This antibody is utilized in the investigation of hemophilia, providing a valuable tool for exploring the regulation of coagulation pathways and potential therapeutic interventions.

Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1κ subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.

The Anti-Histone H3 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Histone H3. It is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for use in various biochemical assays where Histone H3 is a focus of study, providing essential insights into chromatin structure and function.

Casdozokitug (SRF-388) is a monoclonal antibody of the IgG1κ subclass that specifically targets interleukin-27 (IL-27). This antibody has been developed for its potential application in modulating immune responses, given IL-27's role in inflammatory processes. Casdozokitug is suitable for use in various immunological assays to study IL-27's biological functions and its implications in immune regulation and disease pathogenesis.

Pacmilimab (CX-072) is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting significant antitumor activity. This monoclonal antibody selectively binds to PD-L1, disrupting its interaction with PD-1 receptors on T cells, thereby enhancing the immune system's ability to attack tumor cells. Pacmilimab is primarily utilized in research focused on the modulation of immune checkpoints in oncology.

Umizortamig is a monoclonal antibody engineered to target CD3E, EGFR, TNFRSF9, PD-L1, and CD3G. This multi-specific antibody is designed for the simultaneous modulation of key immune checkpoints and signaling pathways, potentially enhancing therapeutic efficacy in oncology and immunotherapy applications. Umizortamig's ability to bind multiple targets allows for a coordinated approach in the regulation of immune responses, making it a valuable tool for research in cancer biology and immune regulation.

LIV-1205 (CBA-1205) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Delta-like 1 homolog (DLK1). This antibody is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, the appropriate isotype control is designated as Human IgG1 kappa, Isotype Control.

Bedinvetmab (ZTS-00508841) is a canine-specific monoclonal antibody designed to target nerve growth factor (NGF). By inhibiting the interaction of NGF with its receptors, tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR), Bedinvetmab effectively modulates pain signaling pathways. This antibody is particularly useful for research into the management of osteoarthritis pain in canine models, providing a valuable tool for understanding and potentially mitigating pain mechanisms in dogs.

Amostomig is a humanized IgG1λ2 monoclonal antibody designed to specifically target CD274 and CD47. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

Pegacaristim is a monoclonal antibody designed to exhibit thrombopoietic activity, effectively stimulating the production of platelets. This targeted biological mechanism positions Pegacaristim as a crucial tool in research focused on hematopoiesis and the therapeutic management of conditions associated with thrombocytopenia.

Vanutide cridificar (ACC-001) is a conjugate of the aminoterminal Aβ1-7 peptide. This biologic is specifically designed for use in Alzheimer's disease (AD) research, facilitating the study of amyloid-beta dynamics and pathology in neurodegenerative processes. Its application in experimental models provides a valuable tool for advancing our understanding of AD mechanisms and potential therapeutic targets.

Pinatuzumab is a monoclonal antibody specifically targeting the cell-surface antigen CD22. This antibody is employed primarily in the development of antibody-drug conjugates (ADCs) for the investigation of various diseases, notably non-Hodgkin lymphoma (NHL). Pinatuzumab's specificity for CD22 makes it a valuable tool in research focused on hematological malignancies.

Linavonkibart (SRK 181) is a fully human monoclonal antibody engineered to exhibit high affinity for latent TGFβ1, effectively inhibiting its activation. This selective binding is crucial for its role in modulating cellular processes associated with cancer, making it an essential tool for research in oncology and tumor biology.

Ipilimumab is a fully human monoclonal antibody of the IgG1κ isotype designed to inhibit the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor on T cells. This antibody is utilized in research focused on unresectable or metastatic melanoma (MM), serving as a critical tool in investigating the modulation of immune checkpoints in cancer therapy.

Simridarlimab is a humanized immunoglobulin (Ig) antibody that specifically targets the CD274 and CD47 antigens. This dual targeting approach enhances the antibody's ability to modulate the immune response against cancer cells, making it a valuable tool in oncological research and therapeutic development.

Imgatuzumab (RG 7160) is a humanized monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR). It functions primarily as an immunomodulator. This antibody is utilized in the study of various cancers, providing a valuable tool for researchers exploring the role of EGFR in oncogenic processes and therapeutic interventions.

Iluzanebart is a human monoclonal IgG1 antibody designed as an agonist for human Triggering Receptor Expressed on Myeloid cells 2 (hTREM2). This antibody enhances the survival and functionality of microglia by activating the TREM2 signaling pathway, thereby compensating for deficits in CSF1R (Colony Stimulating Factor 1 Receptor) function. It is specifically developed for use in research related to adult-onset leukoencephalopathy with CSF1R pathology (CSF1R-ALSP), providing a valuable tool for investigating the molecular mechanisms and potential therapeutic targets for this condition.

Tovetumab (MEDI-575) is a monoclonal antibody specifically targeting PDGFRα, designed to inhibit signal transduction pathways mediated by this receptor. This antibody is utilized primarily in the investigation of pathological conditions such as glioblastoma and non-small cell lung cancer (NSCLC), where PDGFRα plays a critical role in disease progression and cellular proliferation. Tovetumab offers a strategic tool for researchers studying the molecular mechanisms and therapeutic interventions related to these cancers.

Mosunetuzumab (BTCT-4465A) is a fully humanized, full-length immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody designed to concurrently target CD20 on B cells and CD3 on T cells. This bispecific nature allows Mosunetuzumab to redirect T cells to engage and eliminate malignant B cells. It is primarily utilized in research focused on relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs), providing a valuable tool for studies aimed at understanding and potentially treating these conditions.

The Anti-LILRB4/ILT3/CD85k Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the LILRB4/ILT3/CD85k antigen, a critical regulatory receptor expressed on the surface of immune cells. With a molecular weight of approximately 144.36 kDa, this antibody serves as a valuable tool for the study of immune checkpoint regulation and potential therapeutic intervention in immune-related disorders.

Gruticibart is a human IgG4 κ monoclonal antibody targeting Factor XI (F11). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is specifically designed for the study of coagulation processes and potential therapeutic interventions related to blood clotting disorders.

Cirevetmab (ZTS-00521426) is a caninized monoclonal antibody specifically designed for targeting Canis lupus familiaris TGFB1. Classified as an immunoglobulin G2-kappa, this antibody serves as an immunomodulator, influencing cellular responses and immune regulation in therapeutic applications. Cirevetmab is engineered for high specificity and efficacy in modulating the biological activity of TGFB1, making it an essential tool for research in canine immunological disorders.

Zanidatamab (ZW25) is a humanized, bispecific monoclonal antibody designed to target two distinct epitopes (ECD2 and ECD4) of the human epidermal growth factor receptor 2 (HER2). This antibody exhibits potent anti-tumor activity by engaging these specific regions, enhancing its therapeutic efficacy in oncology research. Zanidatamab is primarily used in studies investigating the treatment of HER2-positive cancers.

Lesabelimab (LDP) is a monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CD274, also known as PD-L1. CD274 functions as an immune checkpoint ligand that inhibits antitumor immune responses by engaging the PDCD1 (PD-1) receptor. This interaction is crucial for modulating immune system activity, particularly in the suppression of T-cell mediated immunity in various cancers. Lesabelimab is designed to disrupt this interaction, thereby enhancing the body's antitumor immune response. This antibody is pivotal for research focused on cancer immunotherapy and the study of immune checkpoint pathways.